Ulcerative Colitis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Ulcerative Colitis – Pipeline Review, H1 2018’, provides an overview of the Ulcerative Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

– The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects

– The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

AbbVie Inc

AbGenomics International Inc

Abivax SA

Adello Biologics LLC

Akebia Therapeutics Inc

Allergan Plc

Alpha Cancer Technologies Inc

Am-Pharma BV

Amgen Inc

Aptevo Therapeutics Inc

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Atlantic Bio Sci LLC

Atlantic Healthcare Plc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celltrion Inc

ChemoCentryx Inc

ChironWells GmbH

Coherus BioSciences Inc

Cosmo Pharmaceuticals NV

Dr. August Wolff GmbH & Co KG Arzneimittel

EA Pharma Co Ltd

Eli Lilly and Co

Enceladus Pharmaceuticals BV

Enterome Bioscience SA

Ferring International Center SA

Fresenius SE & Co KGaA

Galapagos NV

Genentech Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

IB Pharmaceuticals Inc

iCo Therapeutics Inc.

Inception Sciences Inc

InDex Pharmaceuticals Holding AB

Intas Pharmaceuticals Ltd

Istesso Ltd

Johnson & Johnson

Kaken Pharmaceutical Co Ltd

Keystone Biologics Inc

Kyowa Hakko Kirin Co Ltd

LG Chem Ltd

LIPID THERAPEUTICS GmbH

Lycera Corp

Merck & Co Inc

Miyarisan Pharmaceutical Company Ltd

Morphotek Inc

Nichi-Iko Pharmaceutical Co Ltd

Noxopharm Ltd

Ogeda SA

Oncobiologics Inc

OSE Immunotherapeutics

Palatin Technologies Inc

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Principia Biopharma Inc

Protab Ltd

Protagonist Therapeutics Inc

Protalix BioTherapeutics Inc

Qu Biologics Inc

Re-Pharm Ltd

Rebiotix Inc

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

Sareum Holdings Plc

Seres Therapeutics Inc

Shire Plc

Sigmoid Pharma Ltd

Stelic Institute & Co Inc

sterna biologicals Gmbh & Co KG

Swedish Orphan Biovitrum AB

Synedgen Inc

Synergy Pharmaceuticals Inc

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

Thetis Pharmaceuticals LLC

Tillotts Pharma AG

TopiVert Ltd

Torrent Pharmaceuticals Ltd

TTY Biopharm Company Ltd

UCB SA

Ventria Bioscience

Vivelix Pharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Ulcerative Colitis Overview 8

Ulcerative Colitis Therapeutics Development 9

Ulcerative Colitis Therapeutics Assessment 30

Ulcerative Colitis Companies Involved in Therapeutics Development 44

Ulcerative Colitis Drug Profiles 83

Ulcerative Colitis Dormant Projects 445

Ulcerative Colitis Discontinued Products 452

Ulcerative Colitis Product Development Milestones 454

Appendix 464

List of Tables

List of Tables

Number of Products under Development for Ulcerative Colitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Ulcerative Colitis Pipeline by 4D Pharma PLC, H1 2018

Ulcerative Colitis Pipeline by AbbVie Inc, H1 2018

Ulcerative Colitis Pipeline by AbGenomics International Inc, H1 2018

Ulcerative Colitis Pipeline by Abivax SA, H1 2018

Ulcerative Colitis Pipeline by Adello Biologics LLC, H1 2018

Ulcerative Colitis Pipeline by Akebia Therapeutics Inc, H1 2018

Ulcerative Colitis Pipeline by Allergan Plc, H1 2018

Ulcerative Colitis Pipeline by Alpha Cancer Technologies Inc, H1 2018

Ulcerative Colitis Pipeline by Am-Pharma BV, H1 2018

Ulcerative Colitis Pipeline by Amgen Inc, H1 2018

Ulcerative Colitis Pipeline by Aptevo Therapeutics Inc, H1 2018

Ulcerative Colitis Pipeline by Arena Pharmaceuticals Inc, H1 2018

Ulcerative Colitis Pipeline by Artelo Biosciences Inc, H1 2018

Ulcerative Colitis Pipeline by Atlantic Bio Sci LLC, H1 2018

Ulcerative Colitis Pipeline by Atlantic Healthcare Plc, H1 2018

Ulcerative Colitis Pipeline by Boehringer Ingelheim GmbH, H1 2018

Ulcerative Colitis Pipeline by Bristol-Myers Squibb Co, H1 2018

Ulcerative Colitis Pipeline by Celgene Corp, H1 2018

Ulcerative Colitis Pipeline by Celltrion Inc, H1 2018

Ulcerative Colitis Pipeline by ChemoCentryx Inc, H1 2018

Ulcerative Colitis Pipeline by ChironWells GmbH, H1 2018

Ulcerative Colitis Pipeline by Coherus BioSciences Inc, H1 2018

Ulcerative Colitis Pipeline by Cosmo Pharmaceuticals NV, H1 2018

Ulcerative Colitis Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2018

Ulcerative Colitis Pipeline by EA Pharma Co Ltd, H1 2018

Ulcerative Colitis Pipeline by Eli Lilly and Co, H1 2018

Ulcerative Colitis Pipeline by Enceladus Pharmaceuticals BV, H1 2018

Ulcerative Colitis Pipeline by Enterome Bioscience SA, H1 2018

Ulcerative Colitis Pipeline by Ferring International Center SA, H1 2018

Ulcerative Colitis Pipeline by Fresenius SE & Co KGaA, H1 2018

Ulcerative Colitis Pipeline by Galapagos NV, H1 2018

Ulcerative Colitis Pipeline by Genentech Inc, H1 2018

Ulcerative Colitis Pipeline by Genor BioPharma Co Ltd, H1 2018

Ulcerative Colitis Pipeline by GlaxoSmithKline Plc, H1 2018

Ulcerative Colitis Pipeline by IB Pharmaceuticals Inc, H1 2018

Ulcerative Colitis Pipeline by iCo Therapeutics Inc., H1 2018

Ulcerative Colitis Pipeline by Inception Sciences Inc, H1 2018

Ulcerative Colitis Pipeline by InDex Pharmaceuticals Holding AB, H1 2018

Ulcerative Colitis Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Ulcerative Colitis Pipeline by Istesso Ltd, H1 2018

Ulcerative Colitis Pipeline by Johnson & Johnson, H1 2018

Ulcerative Colitis Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018

Ulcerative Colitis Pipeline by Keystone Biologics Inc, H1 2018

Ulcerative Colitis Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Ulcerative Colitis Pipeline by LG Chem Ltd, H1 2018

Ulcerative Colitis Pipeline by LIPID THERAPEUTICS GmbH, H1 2018

Ulcerative Colitis Pipeline by Lycera Corp, H1 2018

Ulcerative Colitis Pipeline by Merck & Co Inc, H1 2018

Ulcerative Colitis Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2018

Ulcerative Colitis Pipeline by Morphotek Inc, H1 2018

Ulcerative Colitis Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2018

Ulcerative Colitis Pipeline by Noxopharm Ltd, H1 2018

Ulcerative Colitis Pipeline by Ogeda SA, H1 2018

Ulcerative Colitis Pipeline by Oncobiologics Inc, H1 2018

Ulcerative Colitis Pipeline by OSE Immunotherapeutics, H1 2018

Ulcerative Colitis Pipeline by Palatin Technologies Inc, H1 2018

Ulcerative Colitis Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Ulcerative Colitis Pipeline by Pfizer Inc, H1 2018

Ulcerative Colitis Pipeline by Principia Biopharma Inc, H1 2018

Ulcerative Colitis Pipeline by Protab Ltd, H1 2018

Ulcerative Colitis Pipeline by Protagonist Therapeutics Inc, H1 2018

Ulcerative Colitis Pipeline by Protalix BioTherapeutics Inc, H1 2018

Ulcerative Colitis Pipeline by Qu Biologics Inc, H1 2018

Ulcerative Colitis Pipeline by Re-Pharm Ltd, H1 2018

Ulcerative Colitis Pipeline by Rebiotix Inc, H1 2018

List of Figures

List of Figures

Number of Products under Development for Ulcerative Colitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports